

AMENDED

Registered number
06460858


supreme biotech



SUPREME BIOTECHNOLOGIES LTD

Amended Report and Accounts

31 December 2018



SUPREME BIOTECHNOLOGIES LTD
Amended Report and Accounts
Contents

	Page
Directors' report	2
Profit and loss account	3
Balance sheet	4
Notes to the accounts	5
Detailed profit and loss account	8

SUPREME BIOTECHNOLOGIES LTD

Registered number: 06460858

Directors' Report

The directors present their **amended** report and accounts for the year ended 31 December 2018.

Principal activities

The company's principal activity during the year was in the development and marketing of algae-based natural health products in New Zealand and China.

Directors

The following persons served as directors during the year:

DR. RAYMOND JOHN THOMSON (Deceased August 2018)
MR. MAHESH KUMAR SHAH
MR. JOHN GOLLEDGE
MR. CHANDRAKANT VEKARIA

Directors' responsibilities

The directors are responsible for preparing the report and accounts in accordance with applicable law and regulations.

Company law requires the directors to prepare accounts for each financial year. Under that law the directors have elected to prepare the accounts in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the accounts unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit and loss of the company for that period. In preparing these accounts, the directors are required to:

- Select suitable accounting policies and then apply them consistently;
- Make judgements and estimates that are reasonable and prudent;
- Prepare the accounts on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the accounts comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Small company provisions

This report has been prepared in accordance with the provisions in Part 15 of the Companies Act 2006 applicable to companies subject to the small companies' regime.

This report was approved by the board on 31 January 2019 and signed on its behalf.

Amended Accounts

These amended accounts replace the original statutory accounts and are now the statutory accounts for the company. These amended accounts have been prepared as at the date of the original accounts.



Chandrakant Vekaria
Director

SUPREME BIOTECHNOLOGIES LTD
Profit and Loss Account
for the year ended 31 December 2018

	Notes	2018 £	2017 £
Turnover		2,431	3,676
Cost of Sales		(2,798)	(11,122)
Gross Profit / (Loss)		(367)	(7,446)
Administrative expenses		(868)	(21,231)
Other operating income		-	1,374
Operating Profit / (Loss)		(1,235)	(27,303)
Interest payable	2	-	(3,027)
Profit / (Loss) on ordinary activities before taxation		(1,235)	(30,330)
Tax on profit / (loss) on ordinary activities		-	-
Profit / (Loss) for the financial year		(1,235)	(30,330)

SUPREME BIOTECHNOLOGIES LTD
Balance Sheet
as at 31 December 2018

	Notes	2018 £	2017 £
Fixed assets			
Intangible assets	3	-	-
Investments	4	-	1,299,913
			<u>1,299,913</u>
Current assets			
Stocks		-	2,738
Debtors	5	-	572
Cash at bank and in hand		<u>2,714</u>	<u>5,756</u>
		2,714	9,066
Creditors: amounts falling due within one year	6	(2,714)	(42,437)
Net current Assets		<u>(2,714)</u>	<u>(33,371)</u>
Net Assets		<u>-</u>	<u>1,266,542</u>
Capital and reserves			
Called up share capital	7	-	5,762,222
Reserves		-	(4,026,875)
Profit and loss account	8	-	(468,805)
Shareholders' funds		<u>-</u>	<u>1,266,542</u>

The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.

Members have not required the company to obtain an audit in accordance with section 476 of the Act.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

The amended accounts have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006 applicable to companies subject to the small companies' regime.



Chandrakant Vekaria

Director

Approved by the board on 31 January 2019

SUPREME BIOTECHNOLOGIES LTD
Notes to the Accounts
for the year ended 31 December 2018

1 Accounting policies

Basis of preparation

The accounts have been prepared under the historical cost convention and in accordance with the Financial Reporting Standard for Smaller Entities (effective April 2008), with the exception of investments which are presented at fair value.

Turnover

Turnover represents the value, net of value added tax and discounts, of goods provided to customers and work carried out in respect of services provided to customers.

Foreign currencies

Transactions in foreign currencies are recorded at the rate ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the rate of exchange ruling at the balance sheet date. All differences are taken to the profit and loss account.

2 Interest payable

	2018	2017
	£	£
Interest payable	-	3,027

3 Intangible fixed assets

	2018	2017
	£	£
<i>Research and development</i>		
Cost		
Opening Balance	-	7,500
Additions	-	-
At 31 December	-	<u>7,500</u>
Less Amortisation		
At 31 December	-	(7,500)
Net book value		
At 31 December	-	-

SUPREME BIOTECHNOLOGIES LTD
Notes to the Accounts
for the year ended 31 December 2018

4 Investments

	Investments in subsidiary undertakings £
Market Value	
Market Value as at 1 January 2018	<u>1,299,913</u>
Less 'in specie' distribution	(1,299,913)
At 31 December 2018	<u>-</u>

The investment in Supreme Health Nominees Limited was eliminated by an 'in specie' distribution during the year ending 31 December 2018.

5 Debtors

	2018 £	2017 £
Trade debtors	-	572
Amounts owed by group undertakings and undertakings in which the company has a participating interest	-	-
Other debtors	<u>-</u>	<u>-</u>
	<u>-</u>	<u>572</u>

6 Creditors: amounts falling due within one year

	2018 £	2017 £
Trade creditors	(313)	-
Amounts owed to group undertakings and undertakings in which the company has a participating interest	-	(37,160)
Other taxes and social security costs	-	(5,277)
Other creditors	<u>(2,401)</u>	<u>-</u>
	<u>(2,714)</u>	<u>(42,437)</u>

7 Share capital

	Nominal value	2018 Number	2018 £	2017 £
Allotted, called up and fully paid:				
Ordinary shares	£0.10 each	5,013,504	<u>-</u>	<u>5,762,222</u>
	Nominal value	Number	Amount £	
Shares issued during the period:				
Ordinary shares	£0.00 each	-	-	

SUPREME BIOTECHNOLOGIES LTD
Notes to the Accounts
for the year ended 31 December 2018

8 Profit and loss account	2018	2017
	£	£
At 1 January	(468,805)	(417,204)
In Specie Distribution – net	(4,820,376)	-
Solvent Reduction in Capital	5,260,872	-
Intercompany Debt Forgiven	29,544	-
Prior Period Adjustments	-	(21,272)
Profit for the year	<u>(1,235)</u>	<u>(30,329)</u>
At 31 December	<u>-</u>	<u>(468,805)</u>

SUPREME BIOTECHNOLOGIES LTD
Detailed profit and loss account
for the year ended 31 December 2018

	2018	2017
	£	£
Sales	2,431	3,676
Cost of Sales	(2,798)	(11,122)
Gross Profit / (Loss)	(367)	(7,446)
Administrative expenses	(868)	(21,231)
Other operating income	-	1,374
Operating Profit / (Loss)	(1,235)	(27,303)
Interest payable	-	(3,027)
Profit / (Loss) on ordinary activities before taxation	(1,235)	(30,330)
Tax on profit / (loss) on ordinary activities	-	-
Profit / (Loss) for the financial year	(1,235)	(30,330)

SUPREME BIOTECHNOLOGIES LTD
Detailed profit and loss account
for the year ended 31 December 2018

	2018 £	2017 £
Sales		
Sales	2,431	3,676
Cost of Sales		
Direct Expenses	2,798	11,122
Administrative Expenses		
Employee Costs:		
Wages and Salaries/Commissions	-	1,988
Travel and subsistence	-	13,992
	-	15,980
Premises Costs:		
Rent & Office Costs	-	3,279
	-	3,279
General administrative expenses:		
Bank Charges	155	220
Sundry expenses	-	60
	155	280
Legal and professional costs:		
Accountancy fees	713	1,292
Marketing support	-	400
	713	1,692
	868	21,231
Other Operating Income		
Other operating income	-	1,374
	-	1,374
Net Interest Income and Expenses		
Interest payable	-	(3,027)
	-	(3,027)